Among the 4,076 participants, 80% were receiving ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors, and 15.2% were on SGLT2 inhibitors
"Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats"
The degree and speed of regain varies, but the pattern is consistent across clinical trials and real-world data
Personalized dietary advice and visual aids from dietitians are essential for optimizing outcomes in patients using GLP-1 therapies, showing that communication and side effect management plays a vital role in sustainable weight management
Endocr Rev
Our study also indicates that liver-targeted TR agonists could be tested for the treatment of type 2 diabetes in the future